Amphastar Pharmaceuticals (AMPH) Expected to Release Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.8590 per share and revenue of $197.52 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The firm had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. On average, analysts expect Amphastar Pharmaceuticals to post $2.43 EPS for the current fiscal year and $2.55 EPS for the next fiscal year.

Amphastar Pharmaceuticals Stock Up 0.3%

Shares of AMPH opened at $27.12 on Wednesday. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a 12 month low of $16.65 and a 12 month high of $29.52. The firm’s 50 day moving average is $24.98 and its 200-day moving average is $22.29. The stock has a market capitalization of $1.15 billion, a PE ratio of 10.81, a P/E/G ratio of 5.27 and a beta of 0.93.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203 shares of the company’s stock, valued at approximately $4,050,719.82. The trade was a 5.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William Peters sold 8,180 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $22.48, for a total transaction of $183,886.40. Following the completion of the sale, the chief financial officer owned 172,846 shares in the company, valued at approximately $3,885,578.08. The trade was a 4.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 33,479 shares of company stock worth $763,922 over the last 90 days. Insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on AMPH shares. Barclays increased their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th. Weiss Ratings upgraded shares of Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 16th. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $22.50.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.